The DUSP3 Knockout HGC-27 Polyclonal Cells product from Ascent Research is a genetically modified human gastric carcinoma cell population designed for loss-of-function studies. This polyclonal pool is generated using CRISPR/Cas9-mediated disruption of the DUSP3 gene, resulting in a heterogeneous mixture of knockout cells that faithfully recapitulates the native cellular diversity of the parental line. The polyclonal format eliminates clonal artifacts and provides a robust model for investigating gene function in a physiologically relevant context, without the need for single-cell cloning.
The parental HGC-27 cell line is a well-characterized human gastric carcinoma line originally isolated from a lymph node metastasis of a gastric adenocarcinoma patient. As a metastatic derivative, HGC-27 retains key features of aggressive gastric cancer, including rapid proliferation, invasive potential, and responsiveness to mitogenic and stress signals. This makes it an ideal host for studying molecular mechanisms driving gastric cancer progression and the metastatic cascade, particularly in signaling networks that govern cell fate decisions.
At the molecular level, DUSP3 encodes a dual-specificity protein phosphatase that specifically dephosphorylates phospho-ERK1/2 and phospho-JNK1/2, key terminal kinases of the MAPK/ERK and JNK signaling pathways. By removing activating phosphate groups, DUSP3 directly attenuates signal transduction cascades that promote cell proliferation, survival, and immune cell activation. The enzyme is regulated downstream of upstream activators such as EGFR signaling and T cell receptor (TCR) engagement, and it can also be induced by oxidative stress. Its catalytic targets include the major proline-directed MAP kinases ERK1, ERK2, JNK1, and JNK2, which in turn phosphorylate transcription factors such as c-Jun, c-Fos, and ELK1. These factors assemble into the AP-1 complex, a master regulator of gene expression programs involved in cell cycle progression, apoptosis, and inflammatory responses.
In the HGC-27 background, knockout of DUSP3 disrupts this negative feedback loop, causing sustained hyperphosphorylation of ERK and JNK and consequent constitutive activation of MAPK pathway outputs. This aberrant signaling is expected to drive enhanced cellular proliferation, resistance to apoptosis, and increased motility??phenotypes directly relevant to the metastatic behavior of gastric cancer. Because HGC-27 cells already harbor metastatic traits from their lymph node origin, the DUSP3-deficient derivative serves as an acute model to dissect the specific contribution of MAPK pathway overactivation to gastric cancer aggressiveness and to identify potential therapeutic vulnerabilities.
This polyclonal knockout model is valuable for a broad spectrum of research applications. It enables detailed investigation of DUSP3 as a tumor suppressor in gastric cancer, interrogation of MAPK signaling dynamics, and modeling of gastric cancer progression under conditions of enhanced MAPK activity. Researchers can employ standard assays such as western blotting for phospho-ERK, RT-qPCR for AP-1 target gene induction, and RNA-seq to map global transcriptional changes. Functional assays??including cell proliferation, apoptosis, migration, and drug sensitivity studies??can be implemented to assess the impact of DUSP3 loss on oncogenic properties and therapeutic response. For further information or to inquire about this product, please contact Ascent Research.
